Plasma and Urinary Metanephrines Determined by an Enzyme Immunoassay, but not Serum Chromogranin A for the Diagnosis of Pheochromocytoma in Patients with Adrenal Mass

Abstract

Adrenal pheochromocytomas are neoplasms characterized by catecholamine excess. Determination of metanephrines by high-pressure liquid chromatography has been well established for the diagnosis of pheochromocytomas, demonstrating high sensitivity and specificity. This study evaluates the diagnostic value of newly available enzyme immunoassays for metanephrines in plasma and urine. Chromogranin A was studied as a potential additional diagnostic tool. Spontaneous blood samples and 24-h urine samples were collected in 149 subjects, including 24 histologically proven pheochromocytomas, 17 aldosterone-secreting and 21 cortisol-secreting adrenal adenomas, 30 nonfunctioning adrenal masses, 15 patients with essential hypertension and 42 healthy normotensive volunteers. Plasma and urinary metanephrine and normetanephrine as well as chromogranin A were determined and putative thresholds were calculated by ROC analysis.

Plasma free normetanephrine was found to be the best single parameter with the highest sensitivity (89.5%) and specificity (98.3%) using a threshold of 167 pg/ml. Analysis of the combination of plasma free metanephrines revealed a similar sensitivity with lower specificity of 90.0%. Considering both urinary parameters demonstrated a slightly higher sensitivity (92.9%) with lower specificity (77.6%). ROC analysis revealed a threshold of 215 µg/l for chromogranin A with rather low sensitivity (73.9%) and specificity (74.2%). A weak positive correlation was found between the tumor size of pheochromocytomas and plasma metanephrine (r=0.53, p≤0.05) as well as chromogranin A (r=0.60, p≤0.01).

In conclusion, plasma free and urinary metanephrines measured by enzyme immunoassays are convenient and reliable parameters for the diagnosis of pheochromocytoma. In contrast, CgA demonstrated poor sensitivity and specificity.

Key words

pheochromocytomas - enzyme immunoassays - catecholamines - adrenal mass - hypertension

• References

• 1 Pacak K, Eisenhofer G, Ahlman H et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007; 3: 92-102
• 2 Unger N, Pitt C, Schmidt IL et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 2006; 154: 409-417
• 3 Mundschenk J, Lehnert H. Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 1998; 106: 373-376
• 4 Lenz T, Zorner J, Kirchmaier C et al. Multicenter study on the diagnostic value of a new RIA for the detection of free plasma metanephrines in the work-up for pheochromocytoma. Ann N Y Acad Sci 2006; 1073: 358-373
• 5 Lenders JW, Keiser HR, Goldstein DS et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995; 123: 101-109
• 6 Wassell JT, Wojciechowski WC, Landen DD. Recurrent injury event-time analysis. Stat Med 1999; 18: 3355-3363
• 7 Gao YC, Lu HK, Luo QY et al. Comparison of free plasma metanephrines enzyme immunoassay with (131)I-MIBG scan in diagnosis of pheochromocytoma. Clin Exp Med 2008; 8: 87-91
• 8 Procopiou M, Finney H, Akker SA et al. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. Eur J Endocrinol 2009; 161: 131-140
• 9 Sawka AM, Jaeschke R, Singh RJ et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88: 553-558
• 10 Raber W, Raffesberg W, Bischof M et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 2000; 160: 2957-2963
• 11 Bender H, Maier A, Wiedenmann B et al. Immunoluminometric assay of chromogranin A in serum with commercially available reagents. Clin Chem 1992; 38: 2267-2272
• 12 Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 1994; 78: 1139-1144
• 13 Algeciras-Schimnich A, Preissner CM, Young Jr WF et al. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008; 93: 91-95
• 14 d’Herbomez M, Gouze V, Huglo D et al. Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. J Nucl Med 2001; 42: 993-997
• 15 Bernini GP, Moretti A, Ferdeghini M et al. A new human chromogranin ‘A’ immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer 2001; 84: 636-642
• 16 Grossrubatscher E, Dalino P, Vignati F et al. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf) 2006; 65: 287-293
• 17 Giovanella L, Squin N, Ghelfo A et al. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging 2006; 50: 344-347
• 18 Hsiao RJ, Parmer RJ, Takiyyuddin MA et al. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991; 70: 33-45